|
1.
|
|
33 p, 20.4 MB |
Hyaluronic acid-GPRC5C signalling promotes dormancy in haematopoietic stem cells
/
Zhang, Yu Wei (University of Freiburg, Germany) ;
Mess, Julian (University of Freiburg, Germany) ;
Aizarani, Nadim (University of Freiburg, Germany) ;
Mishra, Pankaj (University of Freiburg, Germany) ;
Johnson, Carys (University of Cambridge, UK) ;
Romero-Mulero, Mari Carmen (University of Freiburg, Germany) ;
Rettkowski, Jasmin (University of Freiburg, Germany) ;
Schönberger, Katharina (University of Freiburg, Germany) ;
Obier, Nadine (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Jäcklein, Karin (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Woessner, Nadine M. (University of Freiburg, Germany) ;
Lalioti, Maria Eleni (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Velasco-Hernandez, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sikora, Katarzyna (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Wäsch, Ralph (University of Freiburg, Germany) ;
Lehnertz, Bernhard (University of Montreal, Canada) ;
Sauvageau, Guy (University of Montreal, Canada) ;
Manke, Thomas (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Menendez, Pablo (Institució Catalana de Recerca i Estudis Avançats) ;
Walter, Sebastian Gottfried (University Hospital of Cologne, Germany) ;
Minguet, Susana (University of Freiburg, Germany) ;
Laurenti, Elisa (University of Cambridge, UK) ;
Günther, Stefan (University of Freiburg, Germany) ;
Grün, Dominic (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Cabezas-Wallscheid, Nina (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany)
Bone marrow haematopoietic stem cells (HSCs) are vital for lifelong maintenance of healthy haematopoiesis. In inbred mice housed in gnotobiotic facilities, the top of the haematopoietic hierarchy is occupied by dormant HSCs, which reversibly exit quiescence during stress. [...]
2022 -  10.1038/s41556-022-00931-x
Nature Cell Biology, Vol. 24 Núm. 7 (july 2022) , p. 1038-1048
|
|
|
2.
|
|
|
3.
|
|
29 p, 5.2 MB |
Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression
/
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortega-Sabater, C. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Thampi, Namitha (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández Fuentes, Narcís (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guerrero Murillo, Mercedes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez Moreno, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Campos, Diana (DiNA Science. S.A) ;
Giménez, Carles (DiNA Science. S.A) ;
Boer, Judith M. (Princess Maxima Center for Pediatric Oncology) ;
den Boer, Monique L. (Department of Pediatric Oncology and Hematology. Erasmus Medical Center - Sophia Children's Hospital) ;
Calvo, Gabriel F. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Camós, Mireia (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Fuster, José Luis (Pediatric Hematology and Oncology Department. Hospital Clínico Universitario Virgen de la Arrixaca. Instituto Murciano de Investigación Biosanitaria (IMIB)) ;
Velasco, P. (Hospital Universitari Vall d'Hebron) ;
Ballerini, Paola (AP-HP. Service of Pediatric Hematology. Hopital Armand Trousseau) ;
Locatelli, Franco (Bambino Gesù Children's Hospital. Catholic University of Sacred Heart) ;
Mullighan, Charles G. (Department of Pathology. St. Jude Children's Research Hospital) ;
Spierings, Diana C.J. (European Research Institute for the Biology of Aging (ERIBA). University of Groningen. University Medical Center Groningen) ;
Foijer, Floris (European Research Institute for the Biology of Aging (ERIBA). University of Groningen. University Medical Center Groningen) ;
Pérez-García, Víctor M. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. [...]
2024 - 10.1038/s44321-023-00006-w
EMBO Molecular Medicine, Vol. 16 Núm. 1 (16 2024) , p. 64-92
|
|
|
4.
|
|
14 p, 2.7 MB |
GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
/
Zhang, Yu Wei (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mess, Julian (University of Freiburg) ;
Lalioti, Maria Eleni (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Romero-Mulero, Mari Carmen (University of Freiburg, Germany) ;
Obier, Nadine (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Karantzelis, Nikolaos (University Medical Center Freiburg, Germany) ;
Rettkowski, Jasmin (University of Freiburg, Germany) ;
Schönberger, Katharina (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Karabacz, Noemie (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Jäcklein, Karin (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Morishima, Tatsuya (Kumamoto University, Japan) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Romecin, Paola (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martinez, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Takizawa, Hitoshi (Kumamoto University, Japan) ;
Shoumariyeh, Khalid (University of Freiburg, Germany) ;
Renders, Simon (Heidelberg University Hospital (Alemanya)) ;
Zeiser, Robert (University of Freiburg, Germany) ;
Pahl, Heike L. (University Medical Center Freiburg, Germany) ;
Béliveau, François (Quebec leukemia cell bank. Hopital Maisonneuve-Rosemont, Montreal, Canada) ;
Hébert, Josee (Quebec leukemia cell bank. Hopital Maisonneuve-Rosemont, Montreal, Canada) ;
Lehnertz, Bernhard (University of Montreal, Canada) ;
Sauvageau, Guy (University of Montreal, Canada) ;
Menendez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cabezas-Wallscheid, Nina (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany)
Leukemia stem cells (LSCs) share numerous features with healthy hematopoietic stem cells (HSCs). G-protein coupled receptor family C group 5 member C (GPRC5C) is a regulator of HSC dormancy. However, GPRC5C functionality in acute myeloid leukemia (AML) is yet to be determined. [...]
2023 - 10.1182/bloodadvances.2023010460
Blood advances, Vol. 7 Núm. 24 (december 2023) , p. 7525-7538
|
|
|
5.
|
|
12 p, 2.5 MB |
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice
/
Galindo Campos, Miguel A. (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Lutfi, Nura (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Bonnin, Sarah (Centre de Regulació Genòmica) ;
Martínez Cáceres, Carlos (Instituto Murciano de Investigación Biosanitaria-Laboratorio de Investigación Biosanitaria-Arrixaca) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Hernández, Violeta (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Martín Caballero, Juan (Instituto Cajal. Consejo Superior de Investigaciones Científicas (CSIC)) ;
Ampurdanés, Coral (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Gimeno, Ramón (Laboratory of Immunology. Department of Pathology) ;
Colomo, Lluís (Hospital del Mar (Barcelona, Catalunya)) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guilbaud, Guillaume (Division of Protein and Nucleic Acid Chemistry. Medical Research Council Laboratory of Molecular Biology) ;
Dantzer, Françoise (Biotechnology and Cell Signaling. Unité Mixte de Recherche (UMR) 7242 Centre National de la Recherche Scientifique. Laboratory of Excellence Medalis. École Supérieure de Biotechnologie de Strasbourg. Strasbourg University) ;
Navarro, Pilar (Hospital del Mar Medical Research Institute. Unidad Asociada IIBB-CSIC) ;
Murga, Matilde (Genomic Instability Group. Spanish National Cancer Research Centre) ;
Fernández Capetillo, Oscar (Science for Life Laboratory. Department of Medical Biochemistry and Biophysics. Karolinska Institutet) ;
Bigas Salvans, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sale, Julian E. (Division of Protein and Nucleic Acid Chemistry. Medical Research Council Laboratory of Molecular Biology) ;
Yélamos, José (Laboratory of Immunology. Department of Pathology)
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. [...]
2022 - 10.1182/blood.2021012805
Blood, Vol. 139 Núm. 2 (13 2022) , p. 228-239
|
|
|
6.
|
|
16 p, 715.0 KB |
A somatic mutation in moesin drives progression into acute myeloid leukemia
/
Yuan, Ouyang. (Lund University) ;
Ugale, Amol. (The University of Vienna) ;
de Marchi, Tommaso (Lund University) ;
Anthonydhason, Vimala (Sahlgrenska Center for Cancer Research. University of Gothenburg) ;
Konturek-Ciesla, Anna (Lund University) ;
Wan, Haixia (Lund University) ;
Eldeeb, Mohamed (Lund University) ;
Drabe, Caroline (Lund University) ;
Jassinskaja, Maria (University of York) ;
Hansson, Jenny (Lund University) ;
Hidalgo, Isabel (Lund University) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cammenga, Jörg (Lund University) ;
Magee, Jeffrey A. (Washington University School of Medicine) ;
Niméus, Emma (Skåne University Hospital (Suècia)) ;
Bryder, David (Lund University) ;
Universitat Autònoma de Barcelona
2022 - 10.1126/sciadv.abm9987
Science advances, Vol. 8 Núm. 16 (april 2022) , p. eabm9987
|
|
|
7.
|
|
13 p, 2.6 MB |
Engraftment characterization of risk-stratified AML in NSGS mice
/
Díaz de la Guardia, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nombela-Arrieta, Cesar (Department of Medical Oncology and Hematology. University and University Hospital Zurich) ;
Bataller, Alex (Hospital Clínic i Provincial de Barcelona) ;
Fuster, José Luis (Instituto Murciano de Investigación Biosanitaria) ;
Anguita, Eduardo (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Vives, Susana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Gomez Casares, Maria Teresa (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Ramírez, Manuel (Instituto de Investigación Hospital Universitario de la Princesa) ;
Lapillonne, Hélène (Haematology Laboratory. AP-HP. Hôpital Armand Trousseau. Centre de Recherche Saint-Antoine CRSA. INSERM. Sorbonne Université) ;
Ramos-Mejia, Verónica (GENYO. Centre for Genomics and Oncological Research. Pfizer/Universidad de Granada/Junta de Andalucía) ;
Rodríguez-Manzaneque, Juan Carlos (GENYO. Centre for Genomics and Oncological Research. Pfizer/Universidad de Granada/Junta de Andalucía) ;
Bueno, Clara (Centro de Investigación Biomédica en Red de Cáncer) ;
Lopez-Millan, Belen (GENYO. Centre for Genomics and Oncological Research. Pfizer/Universidad de Granada/Junta de Andalucía) ;
Menéndez Bujan, Pablo (Institució Catalana de Recerca i Estudis Avançats)
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Disease heterogeneity is well documented, and patient stratification determines treatment decisions. Patient-derived xenografts (PDXs) from risk-stratified AML are crucial for studying AML biology and testing novel therapeutics. [...]
2021 - 10.1182/bloodadvances.2020003958
Blood advances, Vol. 5 Núm. 23 (14 2021) , p. 4842-4854
|
|
|
8.
|
|
36 p, 6.5 MB |
CD133-directed CAR T-cells for MLL leukemia : on-target, off-tumor myeloablative toxicity
/
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zanetti, S. R. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Baroni, Matteo Libero. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez-Martínez, D. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Closa, A. (Universitat Pompeu Fabra) ;
Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marín, P. (Hospital Clínic i Provincial de Barcelona) ;
Eyras, Eduardo (Institució Catalana de Recerca i Estudis Avançats) ;
Varela, Ignacio (Universidad de Cantabria. Departamento de Biología Molecular) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
2019 - 10.1038/s41375-019-0418-8
Leukemia, Vol. 33 Núm. 8 (january 2019) , p. 2090-2125
|
|
|
9.
|
|
11 p, 5.7 MB |
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
/
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zanetti, S. R. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Petazzi, Paolo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez-Martínez, D. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Baroni, Matteo Libero (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster, José Luis (Sección de Oncohematología Pediátrica. Hosp. Clin. Universitario Virgen de la Arrixaca and Instituto Murciano de Investigacion Biosanitaria) ;
Ballerini, Paola (Department of Pediatric Hemato-oncology. Armand-Trousseau Childrens Hospital) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Fuentes, Narcís (Universitat de Vic - Universitat Central de Catalunya) ;
Engel, P. (Universitat de Barcelona. Departament de Biomedicina) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. [...]
2020 - 10.1136/jitc-2020-000896
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (november 2020) , p. e000896
|
|
|
10.
|
|
12 p, 2.0 MB |
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
/
Libero Baroni, Matteo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez Martínez, Diego (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castellà, Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zanetti, S. R (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Díaz de la Guardia, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castaño Cardoso, Julio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Anguita, Eduardo (Hospital Clínico San Carlos (Madrid)) ;
Vives Polo, Susana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Lapillone, Helene (Centre de Recherce Saint-Antoine. Armand-Trousseau Childrens Hospital. Île-de-France) ;
Bras, Anne E. (Immunology Department. Erasmus Medical Center) ;
van der Velden, Vincent H. J. (Immunology Department. Erasmus Medical Center) ;
Junca, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marin, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Bataller, Alex (Hospital Clínic i Provincial de Barcelona) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Vick, Binje (Helmholtz Center. Munich German Research Center for Environmental Health) ;
Jeremias, Irmela (Pediatrics Department. Munich University Hospital Dr von Hauner Children's Hospital. Munchen) ;
Lopez, Angel (Human Immunology Department. Centre for Cancer Biology) ;
Sorigue, Marc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. [...]
2020 - 10.1136/jitc-2020-000845
Journal for immunotherapy of cancer, Vol. 8 Núm. 1 (january 2020)
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
